Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Atara Biotherapeutics (ATRA) Shares Issued (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Shares Issued readings, the most recent being $3.0 million for Q1 2026.

On a quarterly basis, Shares Issued changed N/A to $3.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.4 million, a 87.66% decrease, with the full-year FY2025 number at $1.5 million, up 539.57% from a year prior.
Shares Issued hit $3.0 million in Q1 2026 for Atara Biotherapeutics, up from $1.5 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $35.8 million in Q3 2024 to a low of -$74000.0 in Q2 2024.
Median Shares Issued over the past 5 years was $1.0 million (2022), compared with a mean of $5.3 million.
Biggest five-year swings in Shares Issued: tumbled 100.24% in 2023 and later soared 1364.69% in 2024.
Atara Biotherapeutics' Shares Issued stood at $1.4 million in 2022, then grew by 12.44% to $1.5 million in 2023, then tumbled by 92.43% to $117000.0 in 2024, then skyrocketed by 1146.15% to $1.5 million in 2025, then soared by 102.4% to $3.0 million in 2026.
The last three reported values for Shares Issued were $3.0 million (Q1 2026), $1.5 million (Q4 2025), and $12000.0 (Q3 2025) per Business Quant data.